Sanofi says Sarclisa combos showed benefits in multiple myeloma patients

Sanofi (SNY) says new data from three oral presentations demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma patients. Sarclisa-VRd demonstrated a consistent benefit at every time point up to 60 months and led to the highest minimal residual disease negativity rate of a newly diagnosed multiple myeloma patient regimen with a bortezomib, lenalidomide and dexamethasone backbone, when evaluating exclusively transplant-ineligible patients, according to Sanofi. Higher minimal residual disease negativity rates were observed at both the end of initiation and during maintenance, with 58.1% of patients in the intention-to-treat population treated with Sarclisa-VRd achieving minimal residual disease negativity versus 43.6% of patients in the control arm, according to the company.